Anal carcinoma

Summary

Anal carcinoma (MONDO:0003199) is a cancer and 197 clinical trials. Top therapeutic interventions include mitomycin, cidofovir anhydrous, and cisplatin. A subtype of anus cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 197

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	anal carcinoma
Mondo ID	MONDO:0003199
DOID	DOID:4908
NCIT	C9291
SNOMED CT	448315008
UMLS	C0279637
MedGen	76006
GARD	0027634
Anatomy (UBERON)	UBERON:0001245
Is cancer (heuristic)	yes

Also known as: anal cancer · anal carcinoma · anus carcinoma · Ca anus · cancer of anus · cancer of the anus · carcinoma of anus · carcinoma of the anus

Disease family

This is a subtype of anus cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › rectal disorder › rectal neoplasm › anus neoplasm › anus cancer › anal carcinoma

Related subtypes (3): anus lymphoma, anus sarcoma, anal melanoma

Subtypes (4): anus adenocarcinoma, anal margin carcinoma, anal squamous cell carcinoma, anal canal carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 197.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	103
PHASE2	38
PHASE1	30
PHASE3	15
PHASE1/PHASE2	9
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03233711	PHASE3	ACTIVE_NOT_RECRUITING	Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT04444921	PHASE3	ACTIVE_NOT_RECRUITING	EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
NCT05902533	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation
NCT06207981	PHASE3	RECRUITING	Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA
NCT06465914	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
NCT06866574	PHASE3	ACTIVE_NOT_RECRUITING	A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
NCT00003596	PHASE3	COMPLETED	Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
NCT00003652	PHASE3	COMPLETED	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
NCT00025090	PHASE3	COMPLETED	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer
NCT00068744	PHASE2/PHASE3	TERMINATED	Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
NCT00075868	PHASE3	COMPLETED	Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
NCT01164722	PHASE3	COMPLETED	Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia
NCT01651949	PHASE3	COMPLETED	Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
NCT02135419	PHASE3	COMPLETED	Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
NCT02369939	PHASE3	UNKNOWN	Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy
NCT04157985	PHASE3	COMPLETED	Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
NCT05374252	PHASE3	UNKNOWN	Chemoradiotherapy Combined With or Without PD-1 Blockade in Anal Canal Squamous Carcinoma Patients
NCT02314169	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
NCT02628067	PHASE2	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT04141449	PHASE2	ACTIVE_NOT_RECRUITING	A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation
NCT04166318	PHASE2	ACTIVE_NOT_RECRUITING	Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
NCT04230759	PHASE2	ACTIVE_NOT_RECRUITING	Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
NCT04287868	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies
NCT04432597	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers
NCT04708470	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
NCT04802876	PHASE2	ACTIVE_NOT_RECRUITING	Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
NCT04889742	PHASE2	NOT_YET_RECRUITING	Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors
NCT04929028	PHASE2	ACTIVE_NOT_RECRUITING	Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
NCT05055635	PHASE2	RECRUITING	Pencil Beam Proton Therapy for Recurrences in Anal Cancer Patients Previously Treated With Radiotherapy (DACG 5)
NCT05639972	PHASE1/PHASE2	RECRUITING	E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
NCT05686226	PHASE2	RECRUITING	E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT05969860	PHASE2	RECRUITING	At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
NCT06493019	PHASE2	RECRUITING	Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer
NCT07090174	PHASE2	NOT_YET_RECRUITING	Testing for Safety and Immune Effects of PDS0101, an Anti-HPV Therapy, Among People Living With HIV
NCT07280377	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
NCT07407647	PHASE2	RECRUITING	Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
NCT07425054	PHASE2	NOT_YET_RECRUITING	HPV ctDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Advanced-Stage Anal Cancer
NCT00052897	PHASE1/PHASE2	COMPLETED	SGN-00101 in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia
NCT00093379	PHASE2	COMPLETED	Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
NCT00316888	PHASE2	COMPLETED	Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
MITOMYCIN	4	11
CIDOFOVIR ANHYDROUS	4	2
CISPLATIN	4	2
FLUDEOXYGLUCOSE F 18	4	2
FLUOROURACIL	4	2
ABIRATERONE	4	1
DIPHENHYDRAMINE	4	1
HUMAN PAPILLOMAVIRUS, L1 PROTEIN VIRUS LIKE PARTICLES	4	1
IMIQUIMOD	4	1
NIVOLUMAB	4	1
OCTREOTIDE ACETATE	4	1
PALONOSETRON HYDROCHLORIDE	4	1
PRASTERONE	4	1
RETIFANLIMAB	4	1
TECHNETIUM TC 99M TILMANOCEPT	4	1
TILMANOCEPT	4	1
TIPIRACIL	4	1
TRIFLURIDINE	4	1
BINTRAFUSP ALFA	3	4
ENTINOSTAT	3	1
PELAREOREP	3	1
SPARTALIZUMAB	3	1
EDODEKIN ALFA	2	2
PEXIPEPIMUT-S	2	2
FAPI-46 GA-68	2	1
IMMUNOCYTOKINE NHS-IL12	2	1
ISOXSUPRINE	2	1
NANRILKEFUSP ALFA	2	1
TEMPOL	2	1
UCN-01	2	1